Roheen Raithatha, MD
Otolaryngology · New York, NYNPI 1851558936
Payments from drug & device makers
Across 1,172 payments — averaging $752.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$272K
- Medtronic$209K
- Regeneron Healthcare Solutions, Inc.$128K
- Optinose US, Inc.$107K
- Aerin Medical Inc.$43K
- Intersect ENT, Inc.$39K
- plus $83K from 23 others
What the payments were for
- Consulting fees$88,60511%
- Speaking & faculty fees$623,38875%
- Travel & lodging$85,65810%
- Food & beverage$32,7784%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 292 | $272,466 |
| Medtronic(2 entities) | 245 | $208,681 |
| Regeneron Healthcare Solutions, Inc. | 133 | $128,389 |
| Optinose US, Inc. | 171 | $107,012 |
| Aerin Medical Inc. | 40 | $43,379 |
| Intersect ENT, Inc. | 62 | $39,062 |
| Stryker | 69 | $32,972 |
| GSK | 63 | $29,013 |
| AstraZeneca | 23 | $8,541 |
| Arrinex, Inc. | 3 | $7,359 |
| Regeneron | 3 | $2,478 |
| Neurent Medical Limited | 13 | $1,329 |
| Kaleo, Inc. | 21 | $436 |
| Spirair, Inc. | 1 | $294 |
| Sanofi-aventis U.S. LLC | 5 | $186 |
| Alk-abello, Inc | 6 | $94 |
| Aimmune Therapeutics, Inc. | 3 | $71 |
| Integra Lifesciences Corporation | 2 | $59 |
| Smith+Nephew | 3 | $56 |
| Acclarent, Inc | 2 | $46 |
| Novartis | 2 | $41 |
| Hikma Pharmaceuticals USA | 2 | $40 |
| Amgen | 1 | $38 |
| Phadia US Inc. | 2 | $34 |
| Boehringer Ingelheim | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Merck | 1 | $21 |
| Octapharma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$444,495
- Xhance$90,017
- PROPEL$74,873
- NUVENT$45,514
- VIVAER STYLUS$42,716
- NUCALA$27,938
- FUSION$24,163
- SINUVA$13,247
- RHINAER STYLUS$12,764
- STEALTHSTATION S8 PLATFORM$11,573
- TEZSPIRE$6,763
- ALAR$4,773
- CLARIFIX$1,287
- NEUROMARK Device$1,091
- NEUROMARK Radiofrequency Console$879
- XPRESS ENT DILATION SYSTEM$744
- SeptAlign$588
- TURBALIGN$588
- SCOPIS ENT$384
- ENTELLUS MEDICAL REINFORCED ANESTHESIA NEEDLE$384
How this compares
$882,190 in reported general payments places this provider in the 95th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 47 | $176,886 |
| Dupixent SyringeDupilumab | 21 | $71,198 |
| Fluticasone Propionate | 23 | $247 |
| Ipratropium Bromide | 11 | $165 |
| Doxycycline Hyclate | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in New York
- Anthony DelsignoreNew York$966K
- Dennis KrausNew York$524K
- Ashutosh KackerNew York$387K
- Lawrence LustigNew York$383K
- Brett MilesNew York$368K
- Alfred Marc IloretaNew York$342K
- Hae-Ok KimNew York$104K
- Gregory LevitinNew York$48K
- David KaufmanNew York$42K
- Enrique PerezNew York$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.